Richard Straker Iii
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Richard Straker Iii has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
Giorgos C. Karakousis
Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
23 shared publicationsJohn T. Miura
Department of Surgery, Division of Endocrine and Oncologic Surgery, University of Pennsylvania, Philadelphia, PA; Abramson Cancer Center, Philadelphia, PA
17 shared publicationsAdrienne B. Shannon
Department of Surgery, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania
9 shared publications- Cimarron E. Sharon
Department of Surgery Hospital of the University of Pennsylvania Philadelphia Pennsylvania USA
8 shared publications Emily Y. Chu
Department of Dermatology, Perelman School of Medicine University of Pennsylvania Philadelphia Pennsylvania USA
7 shared publications- Giorgos Constantine Karakousis
University of Pennsylvania 16 Philadelphia, PA
7 shared publications
Latest Publications
- Open Access
- 3 May 2026
- Published by Elsevier in SSRN Electronic Journal
From Awareness to Action: Assessing the Impact of Colon Cancer Screening Guideline Changes in the U.S
Highlights• Screening at 45 years old instead of 50 years old increases early colon cancer detection
- 3 May 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessFrom Awareness to Action: Assessing the Impact of Colon Cancer Screening Guideline Changes in the U.S
Highlights• Screening at 45 years old instead of 50 years old increases early colon cancer detection
- 20 January 2024
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 28 (3) , 276-278
Clinical features can distinguish gastrointestinal stromal tumor from other subepithelial gastric tumors
- 20 January 2024
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 28 (3) , 276-278
Clinical features can distinguish gastrointestinal stromal tumor from other subepithelial gastric tumors
- 19 August 2022
- Published by Wiley in Journal of Surgical Oncology
- Vol. 126 (8) , 1471-1480
Impact of the affordable care act's medicaid expansion on presentation stage and perioperative outcomes of colorectal cancer
Background and Objectives: Medicaid expansion has improved healthcare coverage and preventive health service use. To what extent this has resulted in earlier stage colorectal cancer diagnoses and impacted perioperative outcomes is unclear. Methods: This was a retrospective difference‐in‐difference study using the National Cancer Database on adults (40–64) with Medicaid or no insurance, diagnosed with colorectal adenocarcinomas before (2010–2013) and after (2015–2018) expansion. The primary outcome was early‐stage (American Joint Committee on Cancer Stage 0–1) diagnosis. The secondary outcomes were rate of local excision, emergency surgery, postoperative length of stay, rates of minimally invasive surgery, postoperative mortality, and overall survival (OS). Results: Medicaid expansion was associated with an increase in early‐stage diagnoses for patients with colorectal cancers (odds ratio [OR]: 1.28, 95% confidence interval [CI]: 1.15–1.43), an increase in local excision (OR: 1.39, 95% CI: 1.13–1.69), and a decreased rate of emergent surgery (OR: 0.85, 95% CI: 0.75–0.97) and 90‐day mortality (OR: 0.75, 95% CI: 0.59–0.97). Additionally, patients in expansion states postexpansion had an improved 5‐year OS (hazard ratio: 0.88, 95% CI: 0.83–0.94). Conclusions: Insurance coverage expansion may be particularly important for optimizing stage of diagnosis, subsequent survival, and perioperative outcomes for socioeconomically vulnerable patients.
- 19 August 2022
- Published by Wiley in Journal of Surgical Oncology
- Vol. 126 (8) , 1471-1480
Impact of the affordable care act's medicaid expansion on presentation stage and perioperative outcomes of colorectal cancer
Background and Objectives: Medicaid expansion has improved healthcare coverage and preventive health service use. To what extent this has resulted in earlier stage colorectal cancer diagnoses and impacted perioperative outcomes is unclear. Methods: This was a retrospective difference‐in‐difference study using the National Cancer Database on adults (40–64) with Medicaid or no insurance, diagnosed with colorectal adenocarcinomas before (2010–2013) and after (2015–2018) expansion. The primary outcome was early‐stage (American Joint Committee on Cancer Stage 0–1) diagnosis. The secondary outcomes were rate of local excision, emergency surgery, postoperative length of stay, rates of minimally invasive surgery, postoperative mortality, and overall survival (OS). Results: Medicaid expansion was associated with an increase in early‐stage diagnoses for patients with colorectal cancers (odds ratio [OR]: 1.28, 95% confidence interval [CI]: 1.15–1.43), an increase in local excision (OR: 1.39, 95% CI: 1.13–1.69), and a decreased rate of emergent surgery (OR: 0.85, 95% CI: 0.75–0.97) and 90‐day mortality (OR: 0.75, 95% CI: 0.59–0.97). Additionally, patients in expansion states postexpansion had an improved 5‐year OS (hazard ratio: 0.88, 95% CI: 0.83–0.94). Conclusions: Insurance coverage expansion may be particularly important for optimizing stage of diagnosis, subsequent survival, and perioperative outcomes for socioeconomically vulnerable patients.
- 28 July 2022
- Published by Wiley in Journal of Surgical Oncology
- Vol. 126 (7) , 1263-1271
Association of type II diabetes mellitus with characteristics and outcomes for patients undergoing sentinel lymph node biopsy for cutaneous melanoma
Background and Objectives: Type II diabetes mellitus (T2DM) can lead to an immunosuppressed state, but whether T2DM is associated with worse outcomes for patients with melanoma has not been well studied.Methods: Consecutive patients diagnosed with clinical stage I–II cutaneous melanoma who underwent sentinel lymph node biopsy at a single institution (2007–2016) were identified. Melanoma characteristics and recurrence/survival outcomes were compared between patients with and without T2DM at the time of melanoma diagnosis.Results: Of 1128 patients evaluated, 111 (9.8%) had T2DM (n = 94 [84.7%] non‐insulin dependent [NID‐T2DM]; n = 17 [15.3%] insulin dependent [ID‐T2DM]). T2DM patients were more likely to be older (odds ratio [OR] 1.04, p < 0.001), male (OR 2.15, p = 0.003), have tumors >1.0 mm (OR 1.88, p = 0.023), and have microsatellitosis (OR 2.29, p = 0.030). Five‐year cumulative incidence of melanoma recurrence was significantly higher for patients with ID‐T2DM (46.7% ID‐T2DM vs. 25.7% NID‐T2DM vs. 17.1% no T2DM, p < 0.001), and on multivariable analysis, ID‐T2DM was independently associated with melanoma recurrence (hazard ratio 2.57, p = 0.015). No difference in 5‐year disease‐specific survival was observed between groups.Conclusions: ID‐T2DM appears to be associated with more advanced melanoma and increased risk for melanoma recurrence. Further study as to whether this reflects differences in tumor biology or host factors is warranted.
- 28 July 2022
- Published by Wiley in Journal of Surgical Oncology
- Vol. 126 (7) , 1263-1271
Association of type II diabetes mellitus with characteristics and outcomes for patients undergoing sentinel lymph node biopsy for cutaneous melanoma
Background and Objectives: Type II diabetes mellitus (T2DM) can lead to an immunosuppressed state, but whether T2DM is associated with worse outcomes for patients with melanoma has not been well studied.Methods: Consecutive patients diagnosed with clinical stage I–II cutaneous melanoma who underwent sentinel lymph node biopsy at a single institution (2007–2016) were identified. Melanoma characteristics and recurrence/survival outcomes were compared between patients with and without T2DM at the time of melanoma diagnosis.Results: Of 1128 patients evaluated, 111 (9.8%) had T2DM (n = 94 [84.7%] non‐insulin dependent [NID‐T2DM]; n = 17 [15.3%] insulin dependent [ID‐T2DM]). T2DM patients were more likely to be older (odds ratio [OR] 1.04, p < 0.001), male (OR 2.15, p = 0.003), have tumors >1.0 mm (OR 1.88, p = 0.023), and have microsatellitosis (OR 2.29, p = 0.030). Five‐year cumulative incidence of melanoma recurrence was significantly higher for patients with ID‐T2DM (46.7% ID‐T2DM vs. 25.7% NID‐T2DM vs. 17.1% no T2DM, p < 0.001), and on multivariable analysis, ID‐T2DM was independently associated with melanoma recurrence (hazard ratio 2.57, p = 0.015). No difference in 5‐year disease‐specific survival was observed between groups.Conclusions: ID‐T2DM appears to be associated with more advanced melanoma and increased risk for melanoma recurrence. Further study as to whether this reflects differences in tumor biology or host factors is warranted.
- 11 July 2022
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 29 (12) , 7261-7264
Contemporary Analysis of Sentinel Lymph Node Biopsy Performance Among Patients with Clinically Localized Merkel Cell Carcinoma
- 11 July 2022
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 29 (12) , 7261-7264
Contemporary Analysis of Sentinel Lymph Node Biopsy Performance Among Patients with Clinically Localized Merkel Cell Carcinoma
- 1 July 2022
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 87 (1) , 169-172
Acral lentiginous melanoma in the era of immune checkpoint blockade and targeted therapy: A National Cancer Database analysis
- 1 July 2022
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 87 (1) , 169-172
Acral lentiginous melanoma in the era of immune checkpoint blockade and targeted therapy: A National Cancer Database analysis
- 25 June 2022
- Published by Springer Nature
- p. 377-384
The Efficacy and Evolution of Surgical Management Based on Cancer Biology
- 25 June 2022
- Published by Springer Nature
- p. 377-384
The Efficacy and Evolution of Surgical Management Based on Cancer Biology